Chronic myeloid leukemia, also known as chronic myelogenous leukemia or CML, is a kind of leukemia that starts in the cells in the bone marrow that form blood, according to the American Cancer Society. CML cells accumulate in the body over time,...
Nilotinib is a selective Bcr/Abl tyrosine kinase inhibitor. This type of medicine is used in treatment of leukemia (specifically ...
Nilotinib (AMN107, trade name Tasigna), in the form of the hydrochloride monohydrate salt, is a tyrosine kinase inhibitor approved for the treatment of chronic ...
Tasigna (nilotinib) is a treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in adults resistant or intolerant to Glivec.
Warning. Nilotinib may cause QT prolongation (an irregular heart rhythm that can lead to fainting, loss of consciousness, seizures, or sudden death).
Nilotinib professional patient advice. Specific and up to date information about Nilotinib.
Studies show nilotinib is 20 to 50 times stronger than imatinib. ... Chemists created nilotinib with the idea of improving the target specificity of an ...
Results. At 12 months, the rates of major molecular response for nilotinib (44% for the 300-mg dose and 43% for the 400-mg dose) were nearly twice that for imatinib ...
Information from the FDA about the approval of nilotinib and the clinical trials that led to the approval.
Nilotinib interferes with the growth of some cancer cells. Nilotinib is used to treat a type of blood cancer called Philadelphia chromosome positive c
This page contains brief information about nilotinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical ...
